Key Highlights

• EIQ shares plummeted 50% to $0.64 on 9 September 2026 — the worst performer on the ASX for the session.

• The FDA issued a Not Substantially Equivalent (NSE) determination for EchoSolv HF's initial 510(k) application.

• The company holds cash at bank of over $105 million as at July 2026, providing a funded runway to pursue regulatory options.

• The NSE determination does not impact the FDA-cleared EchoSolv AS platform or its ongoing US commercialisation.

Shares in Echo IQ Ltd (ASX:EIQ) collapsed 50% to $0.64 on 9 September 2026, the steepest single-session decline on the Australian Securities Exchange, after the company disclosed that the US Food and Drug Administration had issued a Not Substantially Equivalent determination for the initial 510(k) application for EchoSolv HF — its AI-driven heart failure identification product. The announcement, released on 8 September 2026, represents a material setback for a key pillar of the company's US commercial strategy and prompted an immediate and severe repricing of the stock.

Understanding the FDA's NSE Determination

An NSE determination under the 510(k) pathway means the FDA has concluded that the submitted device is not substantially equivalent to a legally marketed predicate device, either because it has a different intended use or different technological characteristics that raise new questions of safety and effectiveness. For Echo IQ, this means EchoSolv HF has not received clearance for commercial use in the United States at this time.

The company indicated that upon receipt of the determination, it immediately engaged its US regulatory and legal advisors, study partners and independent statistical experts in a detailed review of the regulatory matters raised. Echo IQ stated that it believes a pathway forward for clearance under the 510(k) route exists and that it intends to engage directly with the FDA to further clarify the matters identified and assess all available administrative and regulatory options.

Options Under Assessment: Appeals and Resubmission

The administrative and regulatory Options available following an NSE determination include filing a Request for Reconsideration with the FDA's Office of Device Evaluation, submitting an appeal to the FDA's Device Classification Panel, or pursuing a de novo classification request for a novel device type. The company may also opt to gather additional clinical or analytical data and resubmit a modified 510(k) application. Echo IQ stated that the process of reviewing the FDA's feedback will inform the most appropriate and efficient pathway forward.

CEO Dustin Haines acknowledged in management commentary that while the company views certain aspects of the determination differently to the FDA, the regulator's decision provides detailed feedback that can now be assessed and discussed directly with the FDA. He described the company as approaching the next phase from a position of strength.

EchoSolv AS Commercialisation Unaffected

A critical distinction in the announcement is that the NSE determination applies exclusively to EchoSolv HF and does not affect EchoSolv AS — the company's FDA-cleared platform targeting aortic stenosis detection. EchoSolv AS's US commercialisation program, including its customer pipeline, reimbursement pathway development, and strategic relationships, continues uninterrupted. The company intends to use the infrastructure being built around EchoSolv AS as a platform for the future commercialisation of EchoSolv HF, subject to eventual regulatory clearance.

Echo IQ also indicated its intention to continue investing in its broader R&D pipeline, which targets additional disease states and new clinical modalities. This pipeline, the company stated, represents an opportunity to extend the EchoSolv platform across cardiovascular care and into new areas of clinical need.

Balance Sheet Provides Runway to Navigate Setback

One Factor that may limit the severity of the long-term impact of this setback is Echo IQ's financial position. The company reported cash at bank of over $105 million as at July 2026, a figure that provides a material funded runway to pursue the regulatory review process, engage with the FDA, and potentially fund the clinical or analytical work that a modified or resubmitted application may require. The company's US commercial infrastructure, which continues to grow around EchoSolv AS, also represents sunk Investment that retains value regardless of the EchoSolv HF outcome.

However, the scale of the market's reaction — a 50% intraday decline — reflects the extent to which EchoSolv HF's US clearance had been anticipated as a near-term commercial catalyst and had likely been incorporated into prior valuations. The timeline to US clearance has now become materially uncertain.

Conclusion

The FDA's NSE determination for EchoSolv HF is an unambiguous setback for Echo IQ, and the 50% decline in the company's share price reflects the market's assessment of the revised probability and timeline for US commercialisation of this product. The company enters the next phase with a funded balance sheet, a cleared product in EchoSolv AS, and a management team committed to pursuing all available regulatory avenues. How Echo IQ navigates the FDA engagement process — and how long that process takes — will be the central variable investors monitor in the months ahead.